SURMOUNT-1: Tirzepatide 15 mg, the generational leap of 2022 SURMOUNT-1 (Jastreboff et al., NEJM 2022, PMID 35658024) randomized 2,539 obese adults without diabetes to tirzepatide 5, 10, or 15 mg/week or placebo over 72 weeks
Retatrutide vs CagriSema: Next-Gen Weight Loss Medications Compared 28.7% vs 20.4%: Triple agonist meets dual combination in the race for obesity dominance Introduction Two medications are racing toward FDA approval with weight loss results that surpass anything currently available
Differential Diagnosis: Nociceptive and Neuropathic Pain
Instead opt for ground chia and flax together as a gentle way to aid your gut motility and if offers lignans and omega 3 that help with inflammation
Crucially, this action is glucose-dependent, meaning it primarily happens when blood sugar levels are high, such as after a meal
Medscape (2026) 12